Claritev (CTEV) Q2 2026 earnings review
Top-Line Momentum Validated, But Profitability Lags Behind
Claritev delivered its fifth consecutive quarter of top-line growth, with Q2 revenue up 6.6% to $257.5M, prompting a full-year guidance raise. The commercial engine is working: H1 bookings surpassed $70M, tracking comfortably toward the $100M annual goal as the company successfully expands into the TPA, Provider, and Public Sector markets. However, beneath the impressive top-line narrative, earnings quality shows cracks. Adjusted EBITDA grew a meager 1.1% YoY, causing margins to compress by over 300 basis points. The company remains shackled by a massive debt load—$100M in quarterly interest expense completely erased $23.4M of operating income, keeping the bottom line deeply negative (-$59.2M).
🐂 Bull Case
Bookings are Accelerating. With $70M booked in H1, the company is capturing momentum across newly targeted verticals like TPAs (securing multiple 7-figure deals). This diversifies revenue away from traditional payer concentration.
Free Cash Flow generation is Reversing from historical cash burns. Q2 FCF hit $54.6M (up from $36.6M YoY), proving that the core business unit economics can yield actual liquidity when working capital is managed correctly.
🐻 Bear Case
Adjusted EBITDA margins are Decelerating. The drop to 60.5% (down from 63.8% YoY) indicates that expansion into new service verticals and upfront commercial investments are structurally less profitable than the legacy software core.
Net income remains severely constrained. The company is servicing ~$4.6B in debt, costing over $100M in interest expense per quarter. Unless unlevered free cash flow scales massively, debt paydown will remain agonizingly slow.
⚖️ Verdict: ⚪
Neutral. The operational turnaround (Vision 2030) is yielding undeniable top-line and bookings success. However, Claritev is essentially running on a treadmill—having to sprint on sales just to offset margin compression and an unyielding capital structure penalty.
Key Themes
Margin Disconnect: The Cost of Growth
Management touted outperforming Adjusted EBITDA expectations, but the hard data contradicts the celebratory tone. While revenue grew 6.6%, Adjusted EBITDA grew only 1.1%. Consequently, Adjusted EBITDA margin is Decelerating, dropping from 63.8% in 25Q2 to 60.5% in 26Q2. This validates prior concerns that the newly booked services business carries roughly half the margin of the core business, and upfront investments are dragging down the overall profitability profile.
Bookings Momentum Points to Future Revenue Ramp
Commercial execution is Stable and strong. Claritev generated over $70M in bookings in H1 2026, putting it comfortably on pace to hit the $100M annual target (which would represent 50% YoY growth over 2025). Importantly, this includes several seven-figure transactions in the TPA market, confirming that the new go-to-market strategy is resonating with clients. Given the historical 6-12 month lag, this sets up a robust revenue pipeline for 2027.
AI as an Operational Lever
Claritev's deployment of AI is moving beyond buzzwords into quantifiable efficiency gains. Prior call commentary confirmed that AI coding tools have nearly doubled engineering team capacity without adding headcount, and automation of Independent Dispute Resolution (IDR) invoice processing is saving thousands of manual hours. This technological integration is critical to preventing OpEx from spiraling linearly with new logo acquisition.
The Infinite Debt Loop
The balance sheet remains a glaring existential concern. In 26Q2, Claritev generated $23.4M in GAAP Operating Income, but paid $100.2M in interest expense on its ~$4.6B debt pile. Even with improving Unlevered Free Cash Flow, the capital structure acts as a permanent ceiling on equity value creation until major deleveraging occurs.
Impending Headwinds in H2 Comparables
As noted in prior quarters, Claritev recognized high-margin, one-time revenues of approximately $5.4M per quarter through Q2, Q3, and Q4 of 2025. This creates an artificially high baseline for the second half of 2026. If the company misses a step on new client implementations, top-line growth could suddenly appear Decelerating against these difficult YoY comps.
Favorable Macro Backdrop Supports Utilization
Management cited 'favorable market trends' driving the return to top-line growth. Driven by structural healthcare inflation (6-9%) and sustained out-of-network claims volumes, Claritev's percentage-of-savings (PSAV) pricing model inherently benefits from higher underlying medical costs. This inflation serves as a macro tailwind for their core savings business.
Other KPIs
Accelerating significantly from $61.2 million a year ago. A 51% YoY jump, primarily driven by improved working capital management and higher non-cash deferred income tax adjustments, showcasing strong underlying liquidity generation from the core operations.
Up from $72.1M YoY. The adjusted cash conversion ratio jumped to 57% (up from 47% YoY). This metric is the purest view of the company's operational health before the heavy interest penalty is applied.
Total cash (including $14.4M unrestricted and $13.3M restricted) remains razor-thin for a company with $4.6B in debt, though augmented by access to a revolving credit facility. The company drew and repaid heavily on its revolver in H1, ending with $70M outstanding.
Guidance
Accelerating. Raised from prior $985M-$1B range. At the midpoint ($1.01B), this implies ~4.6% YoY growth versus FY25's $965.4M. This indicates strong confidence in near-term implementation pipelines despite tough H2 comparables.
Stable. Raised slightly from the prior $605M-$615M range. At the $615M midpoint, it implies roughly 2% YoY growth from FY25's $602.6M. The fact that revenue is guided up ~4.6% but EBITDA is guided up only ~2% confirms the ongoing structural margin compression.
Reversing. Raised from $0-$10M. Claritev expects to end the year cash-flow positive after posting a -$12.3M FCF deficit in FY25. Demonstrates improved discipline around CapEx ($160-$170M guidance maintained) and working capital.
Key Questions
Margin Floor in 'The Way Up'
Adjusted EBITDA margin contracted over 300 bps YoY to 60.5%. As the revenue mix shifts further toward new service verticals and Public Sector contracts, where do you view the structural long-term margin floor for the consolidated business?
Deleveraging Pathway
With quarterly interest expense ($100M+) consistently eroding operating income, and only modest Free Cash Flow generation guided for the year, what is the strategic roadmap for organically or strategically deleveraging the $4.6B balance sheet?
H2 Comparable Dynamics
You previously highlighted ~$5.4M in one-time, 100%-margin revenues impacting Q3 and Q4 2025. Given the raised full-year guidance, how much of the $70M in new H1 bookings is required to convert in H2 just to bridge this YoY gap?